Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.39 -0.85%
Revenue Growth %: +36.2%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
SUNB, CULP, KFY, More
Revenue Growth %: +36.2%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $29.94 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $140-150 million, versus prior guidance of $130-145 million and the consensus of $136.7 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
- Texas Instruments (TXN) Reiterated at Neutral by Cantor Fitzgerald on Upside to Earnings Power
- Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
